volume 144 pages 109947

Nebulized Lidocaine in COVID-19, An Hypothesis

Publication typeJournal Article
Publication date2020-11-01
scimago Q3
wos Q4
SJR0.387
CiteScore4.0
Impact factor0.8
ISSN03069877, 15322777
General Medicine
Abstract
Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients’ lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted.
Found 
Found 

Top-30

Journals

1
2
3
Biomedicines
3 publications, 11.54%
Mendeleev Communications
2 publications, 7.69%
Heart and Lung: Journal of Acute and Critical Care
2 publications, 7.69%
Journal of perioperative practice
2 publications, 7.69%
The Open COVID Journal
1 publication, 3.85%
Journal of Oral Medicine and Oral Surgery
1 publication, 3.85%
Therapeutic Delivery
1 publication, 3.85%
Journal of Nanobiotechnology
1 publication, 3.85%
Drug Delivery and Translational Research
1 publication, 3.85%
International Immunopharmacology
1 publication, 3.85%
Journal of Liposome Research
1 publication, 3.85%
Infection, Genetics and Evolution
1 publication, 3.85%
Annals of Medicine and Surgery
1 publication, 3.85%
Clinical Medicine Insights: Case Reports
1 publication, 3.85%
Journal of Anaesthesiology Clinical Pharmacology
1 publication, 3.85%
PeerJ
1 publication, 3.85%
Current Drug Delivery
1 publication, 3.85%
World Neurosurgery
1 publication, 3.85%
Acta Tropica
1 publication, 3.85%
BMC Palliative Care
1 publication, 3.85%
Cells
1 publication, 3.85%
1
2
3

Publishers

1
2
3
4
5
6
Elsevier
6 publications, 23.08%
MDPI
4 publications, 15.38%
Springer Nature
3 publications, 11.54%
SAGE
3 publications, 11.54%
Bentham Science Publishers Ltd.
2 publications, 7.69%
Taylor & Francis
2 publications, 7.69%
OOO Zhurnal "Mendeleevskie Soobshcheniya"
2 publications, 7.69%
Ovid Technologies (Wolters Kluwer Health)
2 publications, 7.69%
EDP Sciences
1 publication, 3.85%
PeerJ
1 publication, 3.85%
1
2
3
4
5
6
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
26
Share
Cite this
GOST |
Cite this
GOST Copy
Ali Z. A., El-Mallakh R. S. Nebulized Lidocaine in COVID-19, An Hypothesis // Medical Hypotheses. 2020. Vol. 144. p. 109947.
GOST all authors (up to 50) Copy
Ali Z. A., El-Mallakh R. S. Nebulized Lidocaine in COVID-19, An Hypothesis // Medical Hypotheses. 2020. Vol. 144. p. 109947.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.mehy.2020.109947
UR - https://doi.org/10.1016/j.mehy.2020.109947
TI - Nebulized Lidocaine in COVID-19, An Hypothesis
T2 - Medical Hypotheses
AU - Ali, Ziad A
AU - El-Mallakh, Rif S.
PY - 2020
DA - 2020/11/01
PB - Elsevier
SP - 109947
VL - 144
PMID - 32505070
SN - 0306-9877
SN - 1532-2777
ER -
BibTex
Cite this
BibTex (up to 50 authors) Copy
@article{2020_Ali,
author = {Ziad A Ali and Rif S. El-Mallakh},
title = {Nebulized Lidocaine in COVID-19, An Hypothesis},
journal = {Medical Hypotheses},
year = {2020},
volume = {144},
publisher = {Elsevier},
month = {nov},
url = {https://doi.org/10.1016/j.mehy.2020.109947},
pages = {109947},
doi = {10.1016/j.mehy.2020.109947}
}